Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Los Angeles, California
- Most recent report
- 10-Q, filed Aug 7, 2026
- Incorporated
- Delaware
- Filings on record
- 239 filings
- On EDGAR
- CIK 1873835
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer Smaller reporting company Emerging growth company
Financials 8 of 22
News 8 of 32
Prospectuses and Registrations 8 of 28
- 424B5 Prospectus supplement for an offering May 21, 2026
- FWP Free writing prospectus May 21, 2026
- S-8 Registration statement for an employee plan Mar 25, 2026
- 424B5 Prospectus supplement for an offering Mar 25, 2026
- S-3 Shelf registration statement Jan 9, 2026
- 424B5 Prospectus supplement for an offering Dec 8, 2025
- FWP Free writing prospectus Dec 8, 2025
- S-3 Shelf registration statement Oct 6, 2025
Proxies 8 of 11
- DEFA14A Extra proxy material Apr 6, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 6, 2026
- DEFA14A Extra proxy material May 19, 2025
- DEFA14A Extra proxy material May 5, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 30, 2025
- DEFA14A Extra proxy material May 21, 2024
- DEF 14A Proxy statement for a shareholder vote Apr 29, 2024
- DEFA14A Extra proxy material Apr 25, 2023
Ownership 8 of 111
- SCHEDULE 13G Large holder reported a passive stake Aug 14, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Aug 13, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jun 5, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
- 4 Insider reported a trade May 29, 2026
Other 8 of 35
- ARS Annual report sent to shareholders Apr 6, 2026
- EFFECT Notice that a registration became effective Jan 22, 2026
- CORRESP Reply to SEC staff Jan 16, 2026
- UPLOAD Comment letter from SEC staff Jan 16, 2026
- EFFECT Notice that a registration became effective Dec 1, 2025
- CORRESP Reply to SEC staff Nov 26, 2025
- ARS Annual report sent to shareholders May 19, 2025
- D May 20, 2024
Everything here comes from Immix Biopharma, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.